Arca Biopharma Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Arca Biopharma Inc's ROA in the second quarter of 2026?
Arca Biopharma Inc recorded a cumulative net loss of $-133 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -13.31%.

However, within the Healthcare sector 360 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3547, from total ROA ranking in the first quarter of 2026 at 4165.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	597.41 %	33.39 %	-42.49 %	23.2 %	955.55 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-133	-116	-105	-107	-105
Return On Assets (TTM)	-13.31 %	-24.99 %	-24.32 %	-20.37 %	-21.02 %
ABIO's Total Ranking	# 3547	# 4165	# 3679	# 3732	# 3914
Total Assets (TTM) in million	2,491	504	489	510	357
Seq. Total Assets Change	393.86 %	3.25 %	-4.23 %	42.81 %	-5.54 %
Seq. Net Income Change	-	-	-	-	-

ABIO's 5 Years Annual ROA >> Back to ABIO Management Effectiveness >> Compare ABIO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 131
Sector	# 361
Overall	# 3424

Return On Assets Statistics
High	Average	Low
-13.12 %	-48.98 %	-113.77 %
(Sep 30 2023)		(Mar 31 2018)

Financial Statements
Arca Biopharma Inc's Assets	$ 2,491 million	ABIO's Balance sheet
Arca Biopharma Inc's Income	$ -41 million	Quarterly ABIO's Income Statement
ABIO's Income by Division		See ABIO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-25.72 %	2144.23 %	-12.12 %	-21.56 %	8.91 %
Total Assets in million	631	850	38	43	55
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-105	-84	-5	-10	-19
Annual Return On Assets	-16.7 %	-9.85 %	-14.1 %	-23.04 %	-35.18 %

ABIO's 5 Years Annual ROA >> Back to ABIO Management Effectiveness >> Compare ABIO ROA to its Competitors

More Return On Assets Ratios
ABIO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ABIO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ABIO's Competitors
Subscribers only: Roa for Arca Biopharma Inc's Suppliers
Subscribers only: Return On Assets for ABIO's Customers

You may also want to know
ABIO's Roi	ABIO's Inventory Turnover Ratio	ABIO's Growth Rates	ABIO's Dividend Comparisons
	ABIO's Profitability Ratios	ABIO's Asset Turnover Ratio	ABIO's Dividend Growth
ABIO's Roe	ABIO's Valuation Ratios	ABIO's Financial Strength Ratios	ABIO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:01:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.